Alcon Inc./€ALC
1D1W1MYTD1Y5YMAX
Capital at risk
About Alcon Inc.
Alcon Inc. is a global medical company specializing in eye care products. Headquartered in Geneva, Switzerland, Alcon operates in the healthcare industry with a focus on ophthalmology. The company offers a range of products including surgical equipment, contact lenses, and vision care products. Founded in 1945 as a small ophthalmic shop, it has grown to serve a diverse global market with operations across multiple countries. Alcon's strategic positioning leverages its extensive research and development capabilities, allowing it to innovate and adapt within the dynamic field of eye care.
- Ticker
- €ALC
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 25,000
- Headquarters
- Geneva, Switzerland
- Website
- www.alcon.com
Alcon Inc. Metrics
BasicAdvanced
€28B
51.61
€1.14
0.69
€0.31
0.52%
Price and volume
Market cap
€28B
Beta
0.69
52-week high
€74.04
52-week low
€52.32
Average daily volume
1.1M
Dividend rate
€0.31
Financial strength
Current ratio
2.092
Quick ratio
1.123
Long term debt to equity
0.215
Total debt to equity
0.245
Dividend payout ratio (TTM)
27.06%
Interest coverage (TTM)
6.69%
Profitability
EBITDA (TTM)
2,082.225
Gross margin (TTM)
57.22%
Net profit margin (TTM)
5.92%
Operating margin (TTM)
12.88%
Effective tax rate (TTM)
13.23%
Revenue per employee (TTM)
€372,440
Management effectiveness
Return on assets (TTM)
2.80%
Return on equity (TTM)
2.94%
Valuation
Price to earnings (TTM)
51.609
Price to revenue (TTM)
3.05
Price to book
1.24
Price to tangible book (TTM)
6.56
Price to free cash flow (TTM)
20.844
Free cash flow yield (TTM)
4.80%
Free cash flow per share (TTM)
2.814
Dividend yield (TTM)
0.52%
Forward dividend yield
0.52%
Growth
Revenue change (TTM)
8.34%
Earnings per share change (TTM)
-39.24%
3-year revenue growth (CAGR)
6.13%
3-year earnings per share growth (CAGR)
21.53%
3-year dividend per share growth (CAGR)
15.85%
Bulls say / Bears say
Alcon launched 10 new products in the first quarter of 2026, including the Clareon TruPlus IOL, driving a 10% year-over-year rise in revenue to $2.69 billion. (Reuters via MarketScreener)
Second-quarter net sales rose 7.9% year-over-year to $2.78 billion, while core diluted EPS of $0.84 beat consensus by over 10%, underpinning management’s decision to raise full-year core EPS growth guidance to 12–15%. (Reuters)
Alcon entered a non-exclusive collaboration with RxSight in July 2026 to co-develop adjustable presbyopia-correcting intraocular lenses, enhancing its long-term innovation pipeline in premium IOLs. (Business Wire)
Alcon’s Q2 2026 operating margin collapsed to 0.4% from 9.6% a year earlier, driven by a $402 million pre-tax impairment on discontinued PowerVision lens programs, signaling setbacks in R&D investments. (Reuters) (EveryTicker)
Although U.S. tariff refunds of around $60 million boosted margins in Q2, management still projects a full-year tariff impact of $40–90 million, highlighting ongoing exposure to trade policy volatility. (Reuters)
First-quarter implantables segment net sales were almost flat and missed LSEG consensus estimates by roughly $20 million due to competitive pressures, indicating softness in key cataract markets. (Reuters via SahmCapital)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.